Bacterial community acquired pneumonia in HIV-infected inpatients in the highly active antiretroviral therapy era

Infection

Volumn 36, Issue 3, 2008, Pages 231-236

  Madeddu, G ^a   Porqueddu, E M ^a   Cambosu, F ^a   Saba, F ^a   Fois, A G ^a   Pirina, P ^a   Mura, M S ^a  

^a UNIVERSITY OF SASSARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIRETROVIRUS AGENT; LEVOFLOXACIN; METHADONE;

ADULT; AGED; ALCOHOL ABUSE; ARTICLE; BACTERIAL INFECTION; CD4 LYMPHOCYTE COUNT; CIGARETTE SMOKING; CLINICAL EVALUATION; COMMUNITY ACQUIRED PNEUMONIA; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PATHOGENESIS; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL SIGNIFICANCE; STREPTOCOCCUS PNEUMONIAE;

ADULT; AGED; AGED, 80 AND OVER; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; ITALY; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; RISK FACTORS; TREATMENT OUTCOME;

EID: 45849148857     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-007-7162-0     Document Type: Article

References (23)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Homberg SD: Declining morbidity and mortality among patients with advanced immunodeficiency virus infection: HIV outpatient study investigators. N Engl J Med 1998; 338: 853-860.
2. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, Knysz B, Dietrich M, Phillips AN, Lundgren JD; EuroSIDA study group: Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362: 22-29.
3. Ancelle-Park R: Expanded European AIDS-case definition. Lancet 1993; 341: 441.
4. Serraino D, Puro V, Boumis E, Angeletti C, Girardi E, Petrosillo N, Ippolito G: Epidemiological aspects of major opportunistic infections of the respiratory tract in person with AIDS: Europe, 1993-2000. AIDS 2003; 17: 2109-2116.
5. Paul S, Gilbert HM, Ziecheck W, Jacobs J, Sepkowitz KA: The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection. AIDS 1999; 13: 415-418.
6. Altès J, Guadarrama M, Force L, Tapiz A, Vilarò J, García I: The impact of highly active antiretroviral therapy on HIV-related hospitalizations in 17 county hospitals in Catalonia, Spain. AIDS 1999; 11: 1418-1419.
7. Floris-Moore M, Yungtai L, Klein R, Budner N, Gourevitch MN, Moskaleva G, Schoenbaum EE: Gender and hospitalization patterns among HIV-infected drug users beforeand after the availability of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 34: 331-337.
8. Benito N, Rañó A, Moreno A, Gonzàlez J, Montserrat L, Agustí C, Danés C, Pumarola T, Miró JM, Torres A, Gatell JM: Pulmonary infiltrates in HIV-Infected patients in the highly active antiretroviral therapy era in Spain. J Acquir Immune Defic Syndr 2001; 27: 35-43.
9. Arozullah AM, Parada J, Bennett CL, Deloria-Knoll M, Chmiel JS, Phan L, Yarnold PA: A rapid staging system for predicting mortality from HIV-associated community acquired pneumonia. Chest 2003; 123: 1151-1160.
10. Baril L, Astagneau P, Nguyen J, Similowsky T, Mengual X, Katlama C, Bricaire F: Pyogenic bacterial pneumonia in human immunodeficiency virus-infected inpatients: a clinical, radiological, microbiolgical, and epidemiological study. Clin Infect Dis 1998; 26: 964-971.
11. Hirshtick RE, Glassroth J, Jordan MC, et al.: Bacterial pneumonia in persons infected with the human immunodeficiency virus: pulmonary complications of HIV Infection Study Group. N Engl J Med 1995; 333: 845-851.
12. Justice AC, Lasky E, McGinnis KA, Skanderson M, Conigliaro J, Fultz SL, Crothers K, Rabeneck L, Rodriguez-Barradas M, Weissmann SB, Bryant K;VACS 3 Project Team Medical disease and alcohol use among veterans with human immunodeficiency infection: A comparison of disease measurement strategies. Med Care 2006; 44: S52-S60.
13. Trotta MP, Ammassari A, Cozzi-Lepri A, Zaccarelli M, Castelli F, Narciso P, Melzi S, De Luca A, Monforte A, Antinori A, for the Adherence Italian Cohort naive Antiretrovirals (AdICONA) and Adherence Spallanzani (AdeSpall) study group: Adherence to highly active antiretroviral therapy is better in patients receiving non nucleoside reverse transcriptase inhibitor-containig regimens than in those receiving protease-inhibitor containing regimens. AIDS 2003; 17: 1099-1102.
14. Burns DN, Hillman D, Neaton JD, et al.: Cigarette smoking, bacterial pneumonia, and other clinical outcomes in HIV-1 infection. Terry Beirn Community Programs for Clinical Research on AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13: 374-383.
15. Nieman RB, Fleming J, Coker RJ, Harris JR, Mitchell DM: The effect of cigarette smoking on the development of AIDS in HIV-1-seropositive individuals. AIDS 1993; 7: 705-710.
16. Wallace JM, Hansen NI, Lavange L, et al.: Respiratory disease trends in the Pulmonary Complications of HIV Infection Study cohort: pulmonary complications of HIV Infection Study Group. Am J Respir Crit Care Med 1997; 155: 72-80.
17. Crothers K, Griffith TA, McGinnis KA, Rodriguez-Barradas MC, Leaf DA, Weissman S, Gibert CL, Butt AA, Justice AC: The impact of cigarette smoking on mortality, quality of life, and comorbid illness among HIV-positive veterans. J Gen Intern Med 2005; 20: 1142-1145.
18. French N, Nakiyingi J, Carpenter LM, Lugada E, Watera C, Moi K, Antvelink D, Mulder D, Janoff EN, Whitworth J, Gilks CF: 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomized and placebo controlled trial. Lancet 2000; 355: 2016-2111.
19. Rodriguez-Barradas MC, Musher DM, Lahart C, Lacke C, Groover J, Watson D, et al.: Antibody to capsular polysaccharids of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine. J Infect Dis 1992; 165: 553-556.
20. Loeliger AF, Rijkers GT, Aerts P, Been-Tiktat A, Hoepelman AIM, van Dijk H, et al.: Deficient antipneumococcal polysaccharide responses in HIV-seropositive patients. FEMS Immunol Med Microbiol 1995; 12: 33-41.
21. Falcò V, Jordano Q, Cruz MJ, Len O, Ribera E, Campins M, Crespo M, Ocaña I, Rodrigo MJ, Pahissa A: Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: one year follow-up study. Vaccine 2006; 24: 2567-2574.
22. Sybil AT, Wallace MR, Rubins JB, Paxton WB, O'Brien J, Janoff EN: Reimmunization with 23-valent pneumococcal vaccine for patients infected with human immunodeficiency virus type-1: clinical, immunologic, and virologic responses. Clin Infect Dis 2002; 34: 813-821.
23. Viale P, Scudeller L, Petrosillo N, Girardi E, Cadeo B, Signorini L, Pagani L, Carosi G: Clinical stability in human immunodoficiency virus-infected patients with community-acquired penumonia. Clin Infect Dis 2004; 38: 271-279.